Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Mimicking Herceptin

Antibody peptidomimetics are not a new concept, although successful examples are rare. But researchers at Pennsylvania State University have developed a small anti-HER2/neu peptide mimetic that they think could challenge Genentech Inc.'s

Read the full 321 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE